北大医药股份有限公司 关于持股 5%以上股东部分股份质押的公告 北大医药股份有限公司（以下简称"公司"）于近日收到持股5%以上股东北大 医疗管理有限责任公司（以下简称"北大医疗"）的告知函，获悉北大医疗持有的 公司34,615,386股股份办理了质押手续。现将相关情况公告如下： 一、股东股份质押基本情况 1、本次股份质押基本情况 | 股东 名称 | 是否为 控股股 东或第 一大股 东及其 一致行 动人 | 本次质押股份 数量（股） | 占其所持 股份比例 | 占公司总股 本比例 | 是否 为限 售股 及限 售类 型 | 是否 为补 充质 押 | 质押 起始日 | 质押 到期日 | 质权 人 | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 北大 医疗 管理 有限 责任 公司 | 否 | 34,615,386 | 52.78% | 5.81% | 否 | 否 | 2025-11-14 | 2026-11-14 | 中国 银行 深圳 东门 支行 | 股票 质押 用于 续贷 融资 补充 运营 资金 | | ...

Core Viewpoint - The arrest of Xu Xiren, Chairman and President of Peking University Pharmaceutical Co., Ltd., due to criminal charges has created significant turmoil in the capital market, raising concerns about the company's future and its operational challenges [2][6]. Company Overview - Xu Xiren, who previously worked at Standard Chartered Bank, took control of Peking University Pharmaceutical in December 2024 for a symbolic price of 1 yuan, acquiring a company valued at nearly 4 billion yuan with a debt of 2.392 billion yuan for just 33 million yuan [3][4]. - Under Xu's leadership, the company began a process of "de-Peking University" to sever ties with its former parent institution, which included a name change and the termination of key partnerships [5][6]. Operational Challenges - The termination of a long-term service contract with Peking University International Hospital in May 2025 resulted in a significant revenue loss, with the hospital accounting for 78.15% of the company's drug distribution revenue in 2024 [6][7]. - The company anticipates a revenue decline of approximately 600 million yuan and a net profit decrease of around 40 million yuan for the second half of 2025 due to the loss of this major client [6][7]. Financial Performance - Peking University Pharmaceutical reported a 47.95% year-on-year decline in revenue for Q3 2025, amounting to 274 million yuan [6][8]. - The company's drug manufacturing business, which generated 623 million yuan in 2024, is being prioritized as a potential growth area, despite facing challenges from increased competition and declining profit margins [7][8]. Management Changes - Frequent management changes have occurred since 2025, with several key personnel resigning and Xu Xiren appointing his associates to leadership positions, raising concerns about the company's expertise in the pharmaceutical sector [8][9]. - The lack of relevant industry experience among the new board members has led to market skepticism regarding the company's operational capabilities [8][9].

11月12日晚间，北大医药（000788）（000788.SZ）发布公告称，公司于近日经有关部门核实，获悉公 司董事长、总裁徐晰人先生因涉嫌刑事犯罪，已被重庆市江北区人民检察院批准逮捕。 同时，其授权公司董事陈岳忠先生代为行使董事长职责，授权公司常务副总裁余孟川先生代为行使总裁 及法定代表人职责。 就在10月29日晚，北大医药公告了徐晰人被刑事拘留的消息，如今靴子落地。 ...

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

证券日报网讯 11月12日晚间，北大医药发布公告称，北大医药股份有限公司（以下简称"公司"）于近 日收到持股5%以上股东北大医疗管理有限责任公司（以下简称"北大医疗"）的通知，获悉北大医疗持 有的公司部分股份办理了解除质押手续。本次解除质押股份数量为34，615，386股。 （编辑 姚尧） ...

Core Viewpoint - The actual controller of Jiuzhou Pharmaceutical has changed as Huaxuande transfers his shares to his daughters, resulting in a shift in control to them due to Huaxuande's advanced age [1][9]. Shareholding Structure - Huaxuande transferred 42.5% of his shares in Zhejiang Zhongbei Jiuzhou Group and 10% in Taizhou Gede Industrial to his daughters, with Huaxuande no longer holding any shares post-transfer [3][9]. - After the transfer, Huaxuande's daughters hold 22.17% and 13.36% of Jiuzhou Pharmaceutical, respectively, while Huaxuande exits the role of actual controller [1][9]. Financial Details - The total consideration for the share transfer was approximately 61.115 million yuan for Zhongbei Group and 700,000 yuan for Taizhou Gede [9]. - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's stock price of 20.23 yuan per share, is approximately 2.5191 billion yuan [7][9]. Background Information - Huaxuande, born in 1943, is the founder of Jiuzhou Pharmaceutical and has gradually stepped back from management roles due to age, having resigned from key positions since 2017 [11][12]. - Jiuzhou Pharmaceutical transitioned from producing chemical raw materials to contract custom development and production since 2008, and it was listed on the Shanghai Stock Exchange in 2014 [11].

Healthcare Policy - National Healthcare Security Administration held a series of discussions on the adjustment of the disease-based payment grouping scheme 3.0, involving over 70 representatives from medical institutions and industry associations [1] Drug and Medical Device Approvals - Shijiazhuang Pharmaceutical Group's application for the listing of Pertuzumab injection has been accepted by the National Medical Products Administration, targeting HER2-positive breast cancer [1] - Huason Pharmaceutical received a registration certificate for its special medical purpose formula food, Ganyimei®, designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders [2] - United Imaging Healthcare's subsidiary obtained a medical device registration certificate for its color Doppler ultrasound diagnostic system, enhancing its product range across various market segments [3] - Yiling Pharmaceutical's application for the listing of Memantine Hydrochloride, a drug for treating moderate to severe Alzheimer's disease, has been approved [4] - Zhifei Biological's clinical trial application for a freeze-dried varicella inactivated vaccine has been accepted by the National Medical Products Administration [10] - Changchun High-tech's subsidiary received approval for a clinical trial of an acellular pertussis-diphtheria-tetanus combined vaccine for adolescents and adults [11] Capital Market Activities - Peking University Pharmaceutical announced the release of 34,615,386 shares from pledge, representing 51.52% of the pledged shares and 5.81% of the total share capital [5] - Kelun Pharmaceutical received approval for a registration of 4 billion yuan in ultra-short-term financing bonds, with a validity period of 2 years [6][7] - Baili Tianheng decided to delay its global offering and listing of H-shares due to current market conditions [8] - Aipeng Medical announced a plan for a shareholder to reduce holdings by up to 1% of total shares, citing personal funding needs [12] - Hendi Pharmaceutical's shareholders plan to collectively reduce their holdings by up to 2.33% of total shares for personal financial planning [13] Financial Adjustments - Baihua Pharmaceutical plans to use 1.91 billion yuan from its capital reserve to cover losses, primarily due to goodwill impairment from a previous major asset restructuring [14]

Core Viewpoint - Recently, Beijing University Pharmaceutical announced that its chairman and president, Xu Xiren, has been arrested by the Chongqing Jiangbei District People's Procuratorate for suspected criminal offenses [1] Group 1: Company Management - The company's board member, Chen Yuezhong, has been authorized to act as chairman [1] - The company's executive vice president, Yu Mengchuan, has been authorized to act as president and legal representative [1] Group 2: Company Operations - The announcement states that the control of Beijing University Pharmaceutical has not changed [1] - The company's board operations are normal [1] - The company's financial and operational management remains normal [1]

Group 1 - The photovoltaic industry faced significant market turbulence due to rumors about a high-level executive from JA Solar stating that a storage platform had failed, which led to a sharp decline in stock prices within the sector [2][15] - The China Photovoltaic Industry Association issued a statement refuting these rumors, emphasizing that the industry is making steady progress and warning against misinformation that could harm the sector's reputation [2][15] Group 2 - The banking sector has shown a remarkable recovery in the fourth quarter, with the Shenwan Banking Index rising nearly 9%, significantly outperforming the broader market [4] - Agricultural Bank of China and Industrial and Commercial Bank of China reached historical highs in their stock prices, with Agricultural Bank's market capitalization surpassing 3 trillion yuan [4] - Over 60 billion yuan flowed into bank-related ETFs in the fourth quarter, indicating a shift in market sentiment towards the banking sector [4][5] Group 3 - AMD's CEO expressed optimism about the AI market, predicting that the total addressable market for AI data centers will exceed 1 trillion dollars by 2030, with a compound annual growth rate of over 40% [6] - AMD aims to capture a double-digit market share in the AI data center chip market, with expected annual revenue from this segment reaching 100 billion dollars within five years [6] Group 4 - Concerns about an AI investment bubble have spread from the stock market to the bond market, with corporate bonds facing sell-offs and widening yield spreads compared to U.S. Treasuries [7] - The market is increasingly wary of the financial implications of large tech companies seeking funding through public debt markets amid fears of an AI bubble [7] Group 5 - The third-quarter monetary policy report from the central bank highlighted the need for balanced macroeconomic policies to support growth while managing risks, with an emphasis on maintaining a stable economic environment [9] - Experts believe that the central bank will implement moderately accommodative monetary policies to achieve the annual growth target of around 5% [9] Group 6 - The Chinese M&A market has seen a significant increase in technology-related mergers, with a 287% year-on-year growth in tech acquisitions since the introduction of new regulations [10] - Traditional industries are also pursuing mergers to adapt and seek new growth avenues, indicating a trend towards consolidation in various sectors [10] Group 7 - OPEC's latest report suggests a potential oversupply in the oil market by 2026, a significant shift from previous forecasts that anticipated prolonged supply shortages [11] - This change in outlook has led to a sharp decline in oil prices, with Brent crude futures dropping nearly 4% following the report [11]

Group 1: Company Announcements - Zhejiang Dongri clarifies that it is not involved in "brain-computer interface" business [1] - Sanyuan Co. introduces seasonal product "milk candy hawthorn," which has a minimal revenue contribution [1] - Century Huatong plans to repurchase shares worth between 500 million to 1 billion [1] Group 2: Project Investments - Yongrong Co. intends to establish a subsidiary to build a 100 MW photovoltaic power station [1] - Weigao Medical plans to invest in a production base for all-cotton water-jet non-woven fabric [1] - Fuchun Environmental plans to invest in a combined heat and power project in Yicheng, Hubei [1] - Haibo Co. aims to invest in high-end components for flywheel energy storage [1] Group 3: Contract Awards - Longjian Co. wins a construction project worth 483 million [1] - Zhejiang Jiaoke is part of a consortium that aims to win a new urbanization project along the Fuchun River [1] - Dash Smart wins the intelligent project for the new Hong Kong Port inspection building [1] Group 4: Equity Transfers - Aerospace Intelligent Equipment plans to transfer 100% equity of its wholly-owned subsidiary Hangzhou Xuanyu [1] Group 5: Shareholding Changes - Aoxing Packaging's controlling shareholder plans to reduce holdings by up to 1.91% [2] - Aipeng Medical's Zhang Hong selected No. 1 intends to reduce holdings by up to 2% [2] - Ruimaite's senior executive Chen Bei plans to reduce holdings by up to 1.76% [3] - Changlian Co.'s director and general manager Xu Feng plans to reduce holdings by up to 206,520 shares [3] Group 6: Other Notable Events - Peking University Pharmaceutical's chairman and president Xu Xiren has been arrested on criminal charges [3] - Haibo Co. signs a strategic cooperation agreement with CATL, committing to procure no less than 200 GWh of electricity over the next three years [3]